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ABSTRACT
Interaction of Tumor-Associated Macrophages (TAMs) with tumor cells gives insights into tumor progression and
into a novel therapeutic strategy. In papillary thyroid cancer, patients with tumors containing TAMs had a better
prognosis than patients without TAMs . In prostatic cancer, the reduced of total TAMs can be used as a novel
prognostic marker. In melanoma maligna, high number of TAMs was statistically significant associated with poor
response to treatment . In breast cancer progression, the role of TAMs is still unclear.
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INTRODUCTION
Tumor-associated macrophages (TAMs) are
heterogenous population of cells that belong to the
mononuclear phagocyte systems and are derived
from blood-borne monocytes that migrate into
tissues where they undergo final differentiation.1 In
tumors development, TAMs have pleiotropic
functions which can influence both in term of
progression as well as in tumor regression. These
differential effects of TAMs are believed to be
regulated by modulation of the host immune system.2
Tumor growth promotion by TAMs can be mediated
by various cytokines and prostanoid that have the
capacity to stimulate tumor cell growth directly and
or may promote tumorigenesis indirectly through
the induction of tumor vasculatures. Macrophages
also have been shown to suppress many T cell and
NK cell anti- tumor responses. Tumor growth
reduction by TAMs can be mediated by non specific
anti tumor cytotoxic mechanism or induction of
specific cell lytic effects.3,4
Interaction of TAMs with tumor cells gives
insights into tumor progression and into a novel
therapeutic strategy. In papillary thyroid cancer,
patients with tumors containing TAMs had a better
prognosis than patients without TAMs.5 In prostatic
cancer there were inverse relationships between
number of TAM and clinical stage. The reduced of
total TAMs can be a novel prognostic marker for
prostatic cancer.6 In melanoma maligna, high
numbers of TAMs in tumor biopsies were
significantly associated with poor response to
treatment.7
Resembles other malignant tumors, breast
cancer progression is also associated with and
dependent upon neovascularization. As the tumor
continues to progress, so does the degree of
neovascularitation. Not surprisingly, poor breast
cancer prognosis has been shown to correlate with
either increasing micro vascular density or
production of various factors that stimulate new
vessel growth. 8 As mentioned above, TAMs
constitute a major component of the leukocytic
infiltrate that have a close correlation with
neovascularization, and the role of TAMs in breast
cancer progression will be described.
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DISCUSSION
A. TAMs in generals
The monocyte develops from a pluripotent stem
cell in the bone marrow under the influence of
soluble hematopoietic growth factors and by physical
interactions with stromal cells as well as extracellular
matrix. The monoblast, which is the earliest cell
commited to the monocytic lineage, differentiates
via a promonocyte into a mature monocyte, which
after a short period (< 24 hours), leaves the bone
marrow and enters the blood stream as a quiescent
(G0/G1) cell. Such monocytes may then
differentiate further into resident tissue macrophages
and, depending on the local microenvironment,
acquire specialized phenotypic characteristics and
diverse functions.9
Macrophages have a pleiotropic biological role.
In the setting of tumors, TAMs have a range of
functions with the capacity to affect diverse aspects
of neoplastic tissues including angiogenesis and
vascularisation, stroma formation and dissolution,
and modulation of tumor cell growth (enhancement
and inhibition). When activated, they can induce
neoplastic cell death (cytotoxicity, apoptosis) and/
or elicit tumor destructive reactions through
alteration of the number of microvasculature.10
The number of macrophages is varies greatly
(10-65%) among different tumors studied. However,
the percentage of TAMs is usually maintained at a
relatively stable level for a particular tumor type
during transplantation into and growth in syngeneic
hosts.10 The infiltration of mononuclear cells is
generally restricted to the stromal areas with few
cells infiltrating into tumor nests and between the
tumor cells themselves. This migration is mediated
by chemotactic factors that induce inflammatory cells
to leave the vascular compartment and egress into
the surrounding areas. Some tumors, however,
produce inhibitors of chemotaxis. The mechanisms
modulating these processes are poorly defined.3,11
B. TAMs and breast cancers
Breast cancers are known to contain a high
proportion of infiltrating leukocytes, includingTAMs.
Tumor cells attract monocytes by producing
chemotactic agents, including MCP-1, M-CSF,
TFG-and undefined mediators. Tumor-derived
signals can induce both pro-and anti-tumor effector
in TAMs. Depending on the signal activations and
susceptibility of tumor target cells, TAM can either
enhance or inhibit tumor growth. As anti-tumor
effector, TAMs can mediate direct anti-tumor
cytotoxicity, produce cytotoxic molecules (H
2
O
2
,
IL-1, TNF-, NO, ROI) and stimulate lymphocyte
responsiveness through presentation of TAAs as well
as production of immunostimulatory cytokines (eg.
IL-2). On the other hand, as pro- tumor effector,
TAMs produce growth factors that promote cancer
cell proliferation, dissemination, enhance
angiogenesis, and suppress lymphocyte
responsiveness via production both of
immunosuppressive cytokines (e.g. IL-10) and
prostanoids.3
In breast cancer, the increase of macrophages
infiltration, and macrophage- mediated angiogenesis
induce the high expression of MCP-1 (monocyte
chemoattractant protein-1) and VEGF (vascular
endothelial growth factor). Monocyte
chemoattractant protein-1 expressions in tumor cells
was significantly correlated with the extent of TAM
infiltration and both MCP-1 and VEGF expression
have been positively correlated with TAM
infiltration, angiogenesis and poor survival.12
Vascular endothelial growth factor promotes the
proliferation, survival and migration of endothelial
cells by binding to its receptors.13 The other factor
responsible for increased macrophage infiltration in
breast cancer is the macrophage colony-stimulating
factor (CSF)-1, which is important not only for
macrophage recruitment but also for tumor
vascularization and progression.14
Tumor-associated macrophages also secrete
proteases that degrade the extracellular matrix, for
example a metalloproteinase (MMP)-9 that has
emerged as an important modulator of angiogenesis
and tumor development. Other proteases such as
urokinase-type plasminogen activator and heparanase,
releaseproangiogeneicgrowthfactors (e.g.FGF-) that
are sequestered by heparan sulphates proteogli, cans
in the extracellular matrix. But, MMP- 9 may also
have an antiangiogenic effect (at later stage) by
processing the a3 chain of type IV collagen to the
angiogenesis inhibitor.Tumor-associatedmacrophages
also release thrombo-spondin-1, interferon-a and
interferon-gwhichareantiangiogenic.Many cytokines
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(e.g. TGF-, IL-1b, IL-6, TNF-) are known to have
pleiotropic effects, stimulating angiogenesis under
certain conditions and inhibiting it under others.11 It
has not yet been known how the net proportion of the
various proangiogenic or antiangiogenic activities of
TAMs is regulated. However, the balance between
angiogenesis promoting, inhibiting and modulating
determine regulation the overall course of blood
vessels formation.
In ductal invasive carcinoma of the breast, high
levels of TAMs are associated with increased tumor
angiogenesis and reduced survival.15 Recent studies
have indicated that in breast cancers the protumor
role of TAMs is dominant and a research in a mouse
model of breast cancer found that TAMs that were
recruited to the tumor just before malignant
conversions are essential for the angiogenic switch.16
These findings establish a causal linkage to explain
clinical correlation between macrophages,
microvessel density and poor prognosis in breast
cancers.
A research related with targeting TAMs as a
novel strategy against breast cancer in murine models
found that legumin-based DNA vaccine can induced
a robust CD8 T cell. This condition reduced the
TAMs density in tumor tissue and resulted in a
marked decrease of pro-angiogenic factors released
by TAMs such as FGF-, TNF-, MMP-9 and
VEGF. This in turn, led to a suppresion both of
tumor angiogenesis, tumor growth and metastasis.17
CONCLUSION
The role of TAMs in breast cancer progression
can either enhance or inhibit tumor growth,
depending on the signal activations and susceptibility
of tumor target cells. The balance between pro-
angiogenic and antiangiogenic activities of TAMs
determines the tumor growth and prognosis.
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